Skip to main content
SpringerLink
Log in

Economic Implications of Endometriosis: A Review

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Endometriosis is a chronic inflammatory disease that can have serious physical and emotional consequences for patients in terms of pain, quality of life, and infertility. Despite affecting about 10% of women, the pathophysiology and economic impact of the disease are not fully understood. This study aimed to review and summarize research articles quantifying the direct and indirect costs of endometriosis in the context of current national and international treatment guidelines. A search including the terms ‘endometriosis’ AND ‘costs’ OR ‘cost of illness’ OR ‘cost analysis’ OR ‘economic burden’ was performed, focusing on studies published between January 2000 and May 2022. Total costs, costs of primary and secondary care, productivity losses, and indirect costs were reported. The medical costs of endometriosis were principally registered in secondary care settings, where surgery was the main cost driver. There was considerable variability of populations and study settings, with the overall direct medical cost range of endometriosis from US$1459 to US$20,239 (2022) per patient per year. An increasing trend has been reported in secondary care costs over time; however, not enough data were available at this time to evaluate inpatient and outpatient costs versus treatment strategies. Similarly, further research is required to evaluate the costs and potential savings associated with new therapies. Numerous studies have evaluated the indirect costs of endometriosis in recent years, finding costs between US$4572 and US$14,079 (2022). Currently, limited data are available on the economic burden of the disease at the patient level.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet. 2021;397(10276):839–52. https://doi.org/10.1016/S0140-6736(21)00389-5.

    Article  PubMed  CAS  Google Scholar 

  2. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41. https://doi.org/10.1007/s13669-017-0187-1.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nat Rev Dis Prim. 2018;4(1):9. https://doi.org/10.1038/s41572-018-0008-5.

    Article  PubMed  Google Scholar 

  4. Collinet P, Fritel X, Revel-Delhom C, Ballester M, Bolze PA, Borghese B, et al. Management of endometriosis: CNGOF/HAS clinical practice guidelines: short version. J Gynecol Obstet Hum Reprod. 2018;47(7):265–74. https://doi.org/10.1016/j.jogoh.2018.06.003.

    Article  PubMed  CAS  Google Scholar 

  5. Members of the Endometriosis Guideline Core Group, Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;26;2022(2):hoac009. https://doi.org/10.1093/hropen/hoac009.

  6. Ulrich U, Buchweitz O, Greb R, Keckstein J, von Leffern I, Oppelt P, et al. National German guideline (S2k): guideline for the diagnosis and treatment of endometriosis: long version: AWMF Registry No. 015-045. Geburtshilfe Frauenheilkd. 2014;74(12):1104–18. https://doi.org/10.1055/s-0034-1383187.

  7. Leyland N, Casper R, Laberge P, Singh SS; SOGC. Endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32(7 Suppl. 2):S1–32 (PMID: 21545757).

  8. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):155–68. https://doi.org/10.1093/humrep/det050.

  9. Blasco-Amaro JA, Sabalete-Moya T, Carlos-Gil AM, Castro-Campos JL, Molina-Linde JM, Viguera-Guerra I, et al. Modelo de atención a las mujeres con endometriosis. Revisión sistemática de guías de práctica clínica. Sevilla: Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS, AETSA, Evaluación de Tecnologías Sanitarias de Andalucía; 2020.

  10. Della Corte L, Barra F, Mercorio A, Evangelisti G, Rapisarda AMC, Ferrero S, et al. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. 2020;16(9):759–68. https://doi.org/10.1080/17425255.2020.1789591.

    Article  PubMed  CAS  Google Scholar 

  11. Soliman AM, Yang H, Du EX, Kelley C, Winkel C. The direct and indirect costs associated with endometriosis: a systematic literature review. Hum Reprod. 2016;31(4):712–22. https://doi.org/10.1093/humrep/dev335.

    Article  PubMed  Google Scholar 

  12. Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL. Economic burden of endometriosis. Fertil Steril. 2006;86(6):1561–72. https://doi.org/10.1016/j.fertnstert.2006.06.015.

    Article  PubMed  Google Scholar 

  13. Simoens S, Hummelshoj L, D’Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum Reprod Update. 2007;13(4):395–404. https://doi.org/10.1093/humupd/dmm010.

    Article  PubMed  CAS  Google Scholar 

  14. Koltermann KC, Dornquast C, Ebert AD, Reinhold T. Economic burden of endometriosis: a systematic review. Ann Reprod Med Treat. 2017;2(2):1015.

    Google Scholar 

  15. Klein S, D’Hooghe T, Meuleman C, Dirksen C, Dunselman G, Simoens S. What is the societal burden of endometriosis-associated symptoms? A prospective Belgian study. Reprod Biomed Online. 2014;28(1):116–24. https://doi.org/10.1016/j.rbmo.2013.09.020.

    Article  PubMed  Google Scholar 

  16. Armour M, Lawson K, Wood A, Smith CA, Abbott J. The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: a national online survey. PLoS ONE. 2019;14(10): e0223316. https://doi.org/10.1371/journal.pone.0223316.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases. Fertil Steril. 2015;103(1):163–71. https://doi.org/10.1016/j.fertnstert.2014.10.011.

    Article  PubMed  Google Scholar 

  18. Estes SJ, Soliman AM, Epstein AJ, Bond JC, Gordon K, Missmer SA. National trends in inpatient endometriosis admissions: patients, procedures and outcomes, 2006–2015. PLoS ONE. 2019;14(9): e0222889. https://doi.org/10.1371/journal.pone.0222889.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Darbà J, Marsà A. Hospital care of endometriosis in Spain: a retrospective multicenter analysis of patient characteristics and costs. Expert Rev Pharmacoecon Outcomes Res. 2022;22(3):481–8. https://doi.org/10.1080/14737167.2021.1936502.

    Article  PubMed  Google Scholar 

  20. Levy AR, Osenenko KM, Lozano-Ortega G, Sambrook R, Jeddi M, Bélisle S, et al. Economic burden of surgically confirmed endometriosis in Canada. J Obstet Gynaecol Can. 2011;33(8):830–7. https://doi.org/10.1016/S1701-2163(16)34986-6.

    Article  PubMed  Google Scholar 

  21. Soliman AM, Surrey E, Bonafede M, Nelson JK, Castelli-Haley J. Real-world evaluation of direct and indirect economic burden among endometriosis patients in the United States. Adv Ther. 2018;35(3):408–23. https://doi.org/10.1007/s12325-018-0667-3.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Soliman AM, Taylor HS, Bonafede M, Nelson JK, Castelli-Haley J. Incremental direct and indirect cost burden attributed to endometriosis surgeries in the United States. Fertil Steril. 2017;107(5):1181-90.e2. https://doi.org/10.1016/j.fertnstert.2017.03.020 (Taylor, Hugh [corrected to Taylor, Hugh S]. PMID: 28476181).

    Article  PubMed  Google Scholar 

  23. Surrey E, Soliman AM, Trenz H, Blauer-Peterson C, Sluis A. Impact of endometriosis diagnostic delays on healthcare resource utilization and costs. Adv Ther. 2020;37(3):1087–99. https://doi.org/10.1007/s12325-019-01215-x.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Prast J, Oppelt P, Shamiyeh A, Shebl O, Brandes I, Haas D. Costs of endometriosis in Austria: a survey of direct and indirect costs. Arch Gynecol Obstet. 2013;288(3):569–76. https://doi.org/10.1007/s00404-013-2793-0.

    Article  PubMed  Google Scholar 

  25. Grundström H, Hammar Spagnoli G, Lövqvist L, Olovsson M. Healthcare consumption and cost estimates concerning Swedish women with endometriosis. Gynecol Obstet Invest. 2020;85(3):237–44. https://doi.org/10.1159/000507326.

    Article  PubMed  Google Scholar 

  26. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27(5):1292–9. https://doi.org/10.1093/humrep/des073.

    Article  PubMed  Google Scholar 

  27. As-Sanie S, Soliman AM, Evans K, Erpelding N, Lanier R, Katz NP. Healthcare utilization and cost burden among women with endometriosis by opioid prescription status in the first year after diagnosis: a retrospective claims database analysis. J Med Econ. 2020;23(4):371–7. https://doi.org/10.1080/13696998.2019.1707212.

    Article  PubMed  CAS  Google Scholar 

  28. Estes SJ, Soliman AM, Zivkovic M, Chopra D, Zhu X. Healthcare resource use and costs associated with opioid initiation among patients with newly diagnosed endometriosis with commercial insurance in the USA. Adv Ther. 2020;37(6):2777–91. https://doi.org/10.1007/s12325-020-01361-7.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Estes SJ, Soliman AM, Zivkovic M, Chopra D, Zhu X. The impact of high-risk and chronic opioid use among commercially insured endometriosis patients on health care resource utilization and costs in the United States. Womens Health (Lond). 2020;16:1745506520965898. https://doi.org/10.1177/1745506520965898.

  30. Malik A, Sinclair J, Ng CHM, Smith CA, Abbott J, Armour M. Allied health and complementary therapy usage in Australian women with chronic pelvic pain: a cross-sectional study. BMC Womens Health. 2022;22(1):37. https://doi.org/10.1186/s12905-022-01618-z.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Arakawa I, Momoeda M, Osuga Y, Ota I, Koga K. Cost-effectiveness of the recommended medical intervention for the treatment of dysmenorrhea and endometriosis in Japan. Cost Eff Resour Alloc. 2018;10(16):12. https://doi.org/10.1186/s12962-018-0097-8.

    Article  Google Scholar 

  32. Bohn JA, Bullard KA, Rodriguez MI, Ecker AM. Stepwise approach to the management of endometriosis-related dysmenorrhea: a cost-effectiveness analysis. Obstet Gynecol. 2021;138(4):557–64. https://doi.org/10.1097/AOG.0000000000004536 (Erratum in: Obstet Gynecol. 2022 Jan 1;139(1):149–51. PMID: 34623067).

    Article  PubMed  Google Scholar 

  33. Grand TS, Basarir H, Jackson LJ. The cost-effectiveness of oral contraceptives compared to ‘no hormonal treatment’ for endometriosis-related pain: an economic evaluation. PLoS ONE. 2019;14(1): e0210089. https://doi.org/10.1371/journal.pone.0210089.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Wang ST, Johnson SJ, Mitchell D, Soliman AM, Vora JB, Agarwal SK. Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. J Comp Eff Res. 2019;8(5):337–55. https://doi.org/10.2217/cer-2018-0124.

    Article  PubMed  Google Scholar 

  35. Wu B, Yang Z, Tobe RG, Wang Y. Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. BJOG. 2018;125(4):469–77. https://doi.org/10.1111/1471-0528.14786.

    Article  PubMed  CAS  Google Scholar 

  36. Sanghera S, Barton P, Bhattacharya S, Horne AW, Roberts TE; PRE-EMPT research group. Pharmaceutical treatments to prevent recurrence of endometriosis following surgery: a model-based economic evaluation. BMJ Open. 2016;6(4):e010580. https://doi.org/10.1136/bmjopen-2015-010580.

  37. Garcia-Tejedor A, Martinez-Garcia JM, Candas B, Suarez E, Mañalich L, Gomez M, et al. Ethanol sclerotherapy versus laparoscopic surgery for endometrioma treatment: a prospective, multicenter, cohort pilot study. J Minim Invasive Gynecol. 2020;27(5):1133–40. https://doi.org/10.1016/j.jmig.2019.08.036.

    Article  PubMed  Google Scholar 

  38. Hernández AV, Otten J, Christ H, Ulrici C, Piriyev E, Ludwig S, et al. Ghost ileostomy: safe and cost-effective alternative to ileostomy after rectal resection for deep infiltrating endometriosis. In Vivo. 2022;36(3):1290–6. https://doi.org/10.21873/invivo.12829.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Nnoaham KE, Hummelshoj L, Webster P, d’Hooghe T, de Cicco NF, de Cicco NC, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366-73.e8. https://doi.org/10.1016/j.fertnstert.2011.05.090.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Simoens S, Meuleman C, D’Hooghe T. Non-health-care costs associated with endometriosis. Hum Reprod. 2011;26(9):2363–7. https://doi.org/10.1093/humrep/der215.

    Article  PubMed  Google Scholar 

  41. Schultz AB, Chen CY, Edington DW. The cost and impact of health conditions on presenteeism to employers: a review of the literature. Pharmacoeconomics. 2009;27(5):365–78. https://doi.org/10.2165/00019053-200927050-00002.

    Article  PubMed  Google Scholar 

  42. Estes SJ, Soliman AM, Yang H, Wang J, Freimark J. A longitudinal assessment of the impact of endometriosis on patients’ salary growth and risk of leaving the workforce. Adv Ther. 2020;37(5):2144–58. https://doi.org/10.1007/s12325-020-01280-7.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019;220(4):354.e1-12. https://doi.org/10.1016/j.ajog.2018.12.039.

    Article  Google Scholar 

  44. Koltermann KC, Schlotmann A, Schröder H, Willich SN, Reinhold T. Economic burden of deep infiltrating endometriosis of the bowel and the bladder in Germany: the statutory health insurance perspective. Z Evid Fortbild Qual Gesundhwes. 2016;118–119:24–30. https://doi.org/10.1016/j.zefq.2016.09.006.

    Article  PubMed  Google Scholar 

  45. Laganà AS, La Rosa VL, Rapisarda AMC, Valenti G, Sapia F, Chiofalo B, et al. Anxiety and depression in patients with endometriosis: impact and management challenges. Int J Womens Health. 2017;16(9):323–30. https://doi.org/10.2147/IJWH.S119729.

    Article  Google Scholar 

  46. Kvaskoff M, Mu F, Terry KL, Harris HR, Poole EM, Farland L, et al. Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update. 2015;21(4):500–16. https://doi.org/10.1093/humupd/dmv013.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Álvarez-Salvago F, Lara-Ramos A, Cantarero-Villanueva I, Mazheika M, Mundo-López A, Galiano-Castillo N, et al. Chronic fatigue, physical impairments and quality of life in women with endometriosis: a case-control study. Int J Environ Res Public Health. 2020;17(10):3610. https://doi.org/10.3390/ijerph17103610.

    Article  PubMed Central  Google Scholar 

  48. Kuenzig ME, Lee L, El-Matary W, Weizman AV, Benchimol EI, Kaplan GG, et al. The impact of inflammatory bowel disease in Canada 2018: indirect costs of IBD care. J Can Assoc Gastroenterol. 2019;2(Suppl. 1):S34-41. https://doi.org/10.1093/jcag/gwy050.

    Article  PubMed  Google Scholar 

  49. Chen I, Thavorn K, Yong PJ, Choudhry AJ, Allaire C. Hospital-associated cost of endometriosis in Canada: a population-based study. J Minim Invas Gynecol. 2020;27(5):1178–87. https://doi.org/10.1016/j.jmig.2019.09.771.

    Article  Google Scholar 

  50. Pynnä K, Räsänen P, Roine RP, Vuorela P, Sintonen H. Where does the money go to? Cost analysis of gynecological patients with a benign condition. PLoS ONE. 2021;16(7): e0254124. https://doi.org/10.1371/journal.pone.0254124.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Oppelt P, Chavtal R, Haas D, Reichert B, Wagner S, Müller A, et al. Costs of in-patient treatment for endometriosis in Germany 2006: an analysis based on the G-DRG-Coding. Gynecol Endocrinol. 2012;28(11):903–5. https://doi.org/10.3109/09513590.2012.683074.

    Article  PubMed  Google Scholar 

  52. Soliman AM, Surrey ES, Bonafede M, Nelson JK, Vora JB, Agarwal SK. Health care utilization and costs associated with endometriosis among women with Medicaid insurance. J Manag Care Spec Pharm. 2019;25(5):566–72. https://doi.org/10.18553/jmcp.2019.25.5.566.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Economics, Universitat de Barcelona, Diagonal 696, 08034, Barcelona, Spain

    Josep Darbà

  2. Department of Health Economics, BCN Health Economics & Outcomes Research S.L., Travessera de Gràcia, 62, 08006, Barcelona, Spain

    Alicia Marsà

Authors
  1. Josep Darbà
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia Marsà
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep Darbà.

Ethics declarations

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

Josep Darbà and Alicia Marsà have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Authors’ contributions

JD outlined the manuscript concept and reviewed and edited the manuscript. AM conducted the literature search and wrote the manuscript.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 47 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Darbà, J., Marsà, A. Economic Implications of Endometriosis: A Review. PharmacoEconomics 40, 1143–1158 (2022). https://doi.org/10.1007/s40273-022-01211-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-022-01211-0

Search

Navigation